Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

A modular analysis of microglia gene expression, insights into the aged phenotype.

Cho CE, Damle SS, Wancewicz EV, Mukhopadhyay S, Hart CE, Mazur C, Swayze EE, Kamme F.

BMC Genomics. 2019 Feb 28;20(1):164. doi: 10.1186/s12864-019-5549-9.

2.

Co-Administration of an Excipient Oligonucleotide Helps Delineate Pathways of Productive and Nonproductive Uptake of Phosphorothioate Antisense Oligonucleotides in the Liver.

Donner AJ, Wancewicz EV, Murray HM, Greenlee S, Post N, Bell M, Lima WF, Swayze EE, Seth PP.

Nucleic Acid Ther. 2017 Aug;27(4):209-220. doi: 10.1089/nat.2017.0662. Epub 2017 Apr 27.

PMID:
28448194
3.

Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis.

Kordasiewicz HB, Stanek LM, Wancewicz EV, Mazur C, McAlonis MM, Pytel KA, Artates JW, Weiss A, Cheng SH, Shihabuddin LS, Hung G, Bennett CF, Cleveland DW.

Neuron. 2012 Jun 21;74(6):1031-44. doi: 10.1016/j.neuron.2012.05.009.

4.

Peptide nucleic acids conjugated to short basic peptides show improved pharmacokinetics and antisense activity in adipose tissue.

Wancewicz EV, Maier MA, Siwkowski AM, Albertshofer K, Winger TM, Berdeja A, Gaus H, Vickers TA, Bennett CF, Monia BP, Griffey RH, Nulf CJ, Hu J, Corey DR, Swayze EE, Kinberger GA.

J Med Chem. 2010 May 27;53(10):3919-26. doi: 10.1021/jm901489k.

5.

Short antisense oligonucleotides with novel 2'-4' conformationaly restricted nucleoside analogues show improved potency without increased toxicity in animals.

Seth PP, Siwkowski A, Allerson CR, Vasquez G, Lee S, Prakash TP, Wancewicz EV, Witchell D, Swayze EE.

J Med Chem. 2009 Jan 8;52(1):10-3. doi: 10.1021/jm801294h.

PMID:
19086780
6.

Comparing in vitro and in vivo activity of 2'-O-[2-(methylamino)-2-oxoethyl]- and 2'-O-methoxyethyl-modified antisense oligonucleotides.

Prakash TP, Kawasaki AM, Wancewicz EV, Shen L, Monia BP, Ross BS, Bhat B, Manoharan M.

J Med Chem. 2008 May 8;51(9):2766-76. doi: 10.1021/jm701537z. Epub 2008 Apr 10.

PMID:
18399648
7.

Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals.

Swayze EE, Siwkowski AM, Wancewicz EV, Migawa MT, Wyrzykiewicz TK, Hung G, Monia BP, Bennett CF.

Nucleic Acids Res. 2007;35(2):687-700. Epub 2006 Dec 19.

8.

Antisense oligonucleotide therapy for neurodegenerative disease.

Smith RA, Miller TM, Yamanaka K, Monia BP, Condon TP, Hung G, Lobsiger CS, Ward CM, McAlonis-Downes M, Wei H, Wancewicz EV, Bennett CF, Cleveland DW.

J Clin Invest. 2006 Aug;116(8):2290-6. Epub 2006 Jul 27.

9.

Evaluation of basic amphipathic peptides for cellular delivery of antisense peptide nucleic acids.

Maier MA, Esau CC, Siwkowski AM, Wancewicz EV, Albertshofer K, Kinberger GA, Kadaba NS, Watanabe T, Manoharan M, Bennett CF, Griffey RH, Swayze EE.

J Med Chem. 2006 Apr 20;49(8):2534-42.

PMID:
16610796
10.

Structure-activity relationship study on a simple cationic peptide motif for cellular delivery of antisense peptide nucleic acid.

Albertshofer K, Siwkowski AM, Wancewicz EV, Esau CC, Watanabe T, Nishihara KC, Kinberger GA, Malik L, Eldrup AB, Manoharan M, Geary RS, Monia BP, Swayze EE, Griffey RH, Bennett CF, Maier MA.

J Med Chem. 2005 Oct 20;48(21):6741-9.

PMID:
16220989
11.

Telomerase reverse transcriptase (hTERT) mRNA and telomerase RNA (hTR) as targets for downregulation of telomerase activity.

Natarajan S, Chen Z, Wancewicz EV, Monia BP, Corey DR.

Oligonucleotides. 2004 Winter;14(4):263-73.

PMID:
15665594
12.

Disruption of WT1 gene expression and exon 5 splicing following cytotoxic drug treatment: antisense down-regulation of exon 5 alters target gene expression and inhibits cell survival.

Renshaw J, Orr RM, Walton MI, Te Poele R, Williams RD, Wancewicz EV, Monia BP, Workman P, Pritchard-Jones K.

Mol Cancer Ther. 2004 Nov;3(11):1467-84.

13.

Identification and functional validation of PNAs that inhibit murine CD40 expression by redirection of splicing.

Siwkowski AM, Malik L, Esau CC, Maier MA, Wancewicz EV, Albertshofer K, Monia BP, Bennett CF, Eldrup AB.

Nucleic Acids Res. 2004 May 17;32(9):2695-706. Print 2004.

14.

Evaluation of C-5 propynyl pyrimidine-containing oligonucleotides in vitro and in vivo.

Shen L, Siwkowski A, Wancewicz EV, Lesnik E, Butler M, Witchell D, Vasquez G, Ross B, Acevedo O, Inamati G, Sasmor H, Manoharan M, Monia BP.

Antisense Nucleic Acid Drug Dev. 2003;13(3):129-42.

PMID:
12954113
15.

Inhibition of hepatic endothelial E-selectin expression by C-raf antisense oligonucleotides blocks colorectal carcinoma liver metastasis.

Khatib AM, Fallavollita L, Wancewicz EV, Monia BP, Brodt P.

Cancer Res. 2002 Oct 1;62(19):5393-8.

16.

Inhibition of telomerase by 2'-O-(2-methoxyethyl) RNA oligomers: effect of length, phosphorothioate substitution and time inside cells.

Elayadi AN, Demieville A, Wancewicz EV, Monia BP, Corey DR.

Nucleic Acids Res. 2001 Apr 15;29(8):1683-9.

17.

Inhibition of C-raf expression by antisense oligonucleotides extends heart allograft survival in rats.

Stepkowski SM, Qu X, Wang ME, Tian L, Chen W, Wancewicz EV, Johnston JF, Bennett CF, Monia BP.

Transplantation. 2000 Aug 27;70(4):656-61.

PMID:
10972225
18.

Oncogenic homeodomain transcription factor E2A-Pbx1 activates a novel WNT gene in pre-B acute lymphoblastoid leukemia.

McWhirter JR, Neuteboom ST, Wancewicz EV, Monia BP, Downing JR, Murre C.

Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11464-9.

20.

Hormone-sensitive lipase in differentiated 3T3-L1 cells and its activation by cyclic AMP-dependent protein kinase.

Kawamura M, Jensen DF, Wancewicz EV, Joy LL, Khoo JC, Steinberg D.

Proc Natl Acad Sci U S A. 1981 Feb;78(2):732-6.

Supplemental Content

Loading ...
Support Center